Abstract
Based on expression profiling we have identified four molecular subgroups of neuroblastoma, which can be distinguished by a 6-gene signature. The fourth subgroup has not been described elsewhere, and efforts are currently made to further investigate this group's specific characteristics.
Introduction
Neuroblastoma (NB) is a highly heterogeneous childhood cancer. Traditionally, it has been categorized into three genomic subtypes: Type 1 (low-risk), Type 2A (intermediate-risk), and Type 2B (high-risk, MYCN-amplified). However, these classifications often fail to predict the clinical course for intermediate cases. This study utilizes unsupervised gene expression profiling to refine these categories and identify a previously overlooked high-risk subgroup.
Methods and Data
The researchers analyzed three independent microarray datasets (De Preter et al., McArdle/Wilzén et al., and Wang et al.) using Principal Components Analysis (PCA) and hierarchical clustering. To simplify the molecular classification, they distilled a broad set of genes into a robust 6-gene signature consisting of ALK, BIRC5, CCND1, MYCN, NTRK1, and PHOX2B.
Identification of a Novel Subgroup
The most striking finding was the consistent identification of a fourth cluster (p4) across all datasets. This group primarily consists of tumors that lack MYCN amplification (MNA-negative) but often harbor 11q deletions. Despite lacking the traditional MYCN high-risk marker, the p4 group exhibited poor overall survival (~50.5% in the validation set), comparable to the MYCN-amplified p3 group.
The 6-Gene Signature
The 6-gene signature proved sufficient to statistically discriminate all four clusters (p < 0.05). Notably:
- p1 (Type 1): Characterized by high NTRK1 expression and 100% survival.
- p3 (Type 2B): Characterized by high MYCN, ALK, BIRC5, and PHOX2B.
- p4 (Novel): Shows low expression of ALK, BIRC5, and PHOX2B, suggesting a different biological driver than the p3 group despite similar poor outcomes.
Conclusion
This study demonstrates that a minimalist 6-gene signature can effectively stratify neuroblastoma patients into four biologically distinct groups. The discovery of the p4 subgroup highlights a critical gap in current clinical risk assessment, identifying a high-risk population that requires further investigation for targeted therapies.
Summary updated